Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage.

• Vos SJ 1 Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands s.vos@maastrichtuniversity.nl.
• Verhey F 1 Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands.
• Frölich L 2 Department of Geriatric Psychiatry, Zentralinstitut für Seelische Gesundheit, University of Heidelberg, Mannheim, Germany.
• Kornhuber J 3 Department of Psychiatry and Psychotherapy, Friedrich-Alexander University of Erlangen, Erlangen, Germany.
• Wiltfang J 4 Department of Psychiatry and Psychotherapy, University Medical Centre (UMG), Georg-August-University, Göttingen, Germany.
• Maier W 5 Department of Psychiatry and Psychotherapy, University of Bonn, German Centre for Neurodegenerative Diseases (DZNE), Bonn, Germany.
• Peters O 6 Department of Psychiatry and Psychotherapy, Charité Berlin, Berlin, Germany.
• Rüther E 7 Department of Psychiatry and Psychotherapy, University of Göttingen, Göttingen, Germany.
• Nobili F 8 Clinical Neurophysiology Service, Department of Neurosciences, Ophthalmology and Genetics, University of Genoa, Genoa, Italy.
• Morbelli S 9 Nuclear Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
• Frisoni GB 10 IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy 11 University Hospitals and University of Geneva, Geneva, Switzerland.
• Drzezga A 12 Department of Nuclear Medicine, University of Cologne, Cologne, Germany.
• Didic M 13 Service de Neurologie et Neuropsychologie, Pôle de neurosciences cliniques, AP-HM Timone, Aix Marseille Université, INS UMR_S 1106, 13005, Marseille, France.
• van Berckel BN 14 Department of Nuclear Medicine and PET Research, VU University Medical CentRE, Amsterdam, The Netherlands.
• Simmons A 15 Department of Neuroimaging, Centre for Neuroimaging Science, King's College London, Institute of Psychiatry, London, UK.
• Soininen H 16 Institute of Clinical Medicine, Neurology, University of Eastern Finland and Neurocenter, Neurology, Kuopio University Hospital, Kuopio, Finland.
• Kłoszewska I 17 Medical University of Lodz, Lodz, Poland.
• Mecocci P 18 Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy.
• Tsolaki M 19 Aristotle University of Thessaloniki, Memory and Dementia Center, 3rd Department of Neurology, "G Papanicolaou" General Hospital, Thessaloniki, Greece.
• Vellas B 20 UMR INSERM 1027, CHU Toulouse, Toulouse, France.
• Lovestone S 21 University of Oxford, Department of Psychiatry, Oxford, UK.
• Muscio C 10 IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy 22 Fondazione Europea Ricerca Biomedica (FERB), Centro di Eccellenza Alzheimer, Ospedale Briolini, Gazzaniga, Bergamo, Italy 23 Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
• Herukka SK 16 Institute of Clinical Medicine, Neurology, University of Eastern Finland and Neurocenter, Neurology, Kuopio University Hospital, Kuopio, Finland.
• Salmon E 24 Memory Clinic, Department of Neurology, CHU Liège, Belgium 25 Cyclotron Research Centre, University of Liège, Liège, Belgium.
• Bastin C 25 Cyclotron Research Centre, University of Liège, Liège, Belgium.
• Wallin A 26 Department of Psychiatry and Neurochemistry, Institute for Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
• Nordlund A 26 Department of Psychiatry and Neurochemistry, Institute for Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
• de Mendonça A 27 Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Portugal.
• Silva D 27 Institute of Molecular Medicine, Faculty of Medicine, University of Lisbon, Portugal.
• Santana I 28 Department of Neurology, Coimbra University Hospital, Coimbra, Portugal.
• Lemos R 29 Faculty of Psychology and Educational Sciences, University of Coimbra, Coimbra, Portugal.
• Engelborghs S 30 Reference Centre for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium 31 Department of Neurology and Memory Clinic, Hospital Network Antwerp, Middelheim and Hoge Beuken, Antwerp, Belgium.
• Van der Mussele S 30 Reference Centre for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behaviour, Institute Born-Bunge, University of Antwerp, Antwerp, Belgium.
• Freund-Levi Y 33 Lund University, Clinical Sciences Malmö, Clinical Memory Research Unit, Lund, Sweden.
• Wallin ÅK 34 Centre des Maladies Cognitives et Comportementales, Institut du Cerveau et de la Moelle épinière, Paris, France; Université Pierre et Marie Curie-Paris 6, AP-HP, Hôpital de la Salpêtrière, Paris, France.
• Hampel H 35 Alzheimer Centre and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
• van der Flier W 35 Alzheimer Centre and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
• Scheltens P 1 Department of Psychiatry and Neuropsychology, Maastricht University, School for Mental Health and Neuroscience, Alzheimer Centre Limburg, Maastricht, The Netherlands 35 Alzheimer Centre and Department of Neurology, Neuroscience Campus Amsterdam, VU University Medical Center, Amsterdam, The Netherlands.
• Visser PJ

Show more…

Alzheimer’s disease

MCI

biomarkers

diagnostic criteria

prognosis

Adult

Aged

Aged, 80 and over

Alzheimer Disease

Biomarkers

Cognitive Dysfunction

Disease Progression

Female

Humans

Male

Middle Aged

Neuropsychological Tests

Prevalence

Prognosis

Survival Analysis